These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34054397)

  • 1. A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir.
    Tarao K; Nozaki A; Komatsu H
    Case Rep Gastroenterol; 2021; 15(1):436-442. PubMed ID: 34054397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
    Takakusagi S; Shimizu M; Yokoyama Y; Kizawa K; Marubashi K; Kosone T; Sato K; Kakizaki S; Takagi H; Uraoka T
    Clin J Gastroenterol; 2020 Dec; 13(6):1303-1309. PubMed ID: 32914297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
    Chan J; Kim JJ; Barrett BK; Hamadeh A; Feld JJ; Wong WWL
    J Viral Hepat; 2021 Feb; 28(2):260-267. PubMed ID: 33065774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
    J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.
    Tahata Y; Sakamori R; Maesaka K; Doi A; Yamada R; Kodama T; Hikita H; Miyazaki M; Nozaki Y; Kaneko A; Oshita M; Tanaka S; Imanaka K; Hiramatsu N; Morishita N; Ohkawa K; Yakushijin T; Sakakibara M; Iio S; Doi Y; Tatsumi T; Takehara T
    Hepatol Res; 2023 Apr; 53(4):301-311. PubMed ID: 36507871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis.
    Ohya K; Imamura M; Teraoka Y; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Mori N; Takaki S; Tsuji K; Aisaka Y; Ishitobi T; Katamura Y; Kodama H; Nabeshima Y; Masaki K; Honda Y; Moriya T; Kohno H; Kohno H; Chayama K
    Hepatol Res; 2020 Nov; 50(11):1234-1243. PubMed ID: 32914512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China.
    Abulitifu Y; Lian J; Adilijiang M; Liu L; Zhao F; Qian W; Zhang Y
    Infect Drug Resist; 2022; 15():6463-6470. PubMed ID: 36353379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    Tahata Y; Hikita H; Mochida S; Kawada N; Enomoto N; Ido A; Yoshiji H; Miki D; Hiasa Y; Takikawa Y; Sakamori R; Kurosaki M; Yatsuhashi H; Tateishi R; Ueno Y; Itoh Y; Yamashita T; Kanto T; Suda G; Nakamoto Y; Kato N; Asahina Y; Matsuura K; Terai S; Nakao K; Shimizu M; Takami T; Akuta N; Yamada R; Kodama T; Tatsumi T; Yamada T; Takehara T
    J Gastroenterol; 2021 Jan; 56(1):67-77. PubMed ID: 33001338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis.
    Shahid S; Asghar S; Mahmood T; Fatima M; Rasheed A; Asghar S
    Cureus; 2023 Sep; 15(9):e45680. PubMed ID: 37868481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
    Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
    J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis.
    Loo JH; Xu WXF; Low JT; Tay WX; Ang LS; Tam YC; Thurairajah PH; Kumar R; Wong YJ
    World J Hepatol; 2022 Jun; 14(6):1248-1257. PubMed ID: 35978662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years.
    Esteban R; Domínguez-Hernández R; Cantero H; Casado MÁ
    Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
    PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
    Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
    J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
    J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
    Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.